RNA疗法2.0:从mRNA疫苗扩展到拼接调节器以及其他领域
Pawan N Karwa1, Nikhil S Sakle2
1Dr. Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune 411018, Maharashtra, India; School of Pharmacy and Research, Dnyaan Prasad Global University, Pune, India.
Biotechnology advances
|March 6, 2026
概括
RNA疗法已经从早期的寡核酸药物发展到像mRNA和循环RNA这样的先进平台. 交付和设计方面的创新正在扩大针对各种疾病的基于RNA的精密医学.
科学领域:
- 生物技术和制药科学 生物技术和制药科学
- 分子医学是分子医学.
- 药物发现和开发 药物发现和开发
背景情况:
- RNA疗法是一种快速发展的药物类别,从早期的药物如反感性寡核酸 (ASOs) 和小干扰RNA (siRNAs) 演变.
- 最初的RNA模式面临挑战,包括核酶不稳定性,低效传递和免疫性,限制了它们的临床应用.
- 最近的突破,特别是mRNA疫苗的突破,源于改进的骨干化学,核酸修饰和向的输送系统,如脂质纳米粒子 (LNP) 和N-乙甲胺 (GalNAc) 结合.
研究的目的:
- 审查RNA治疗药物的演变,从基础的寡核酸药物到下一代平台.
- 突出基于RNA的精密医学的关键进展,持续的挑战和新兴技术.
- 探索RNA技术在各种疾病领域不断扩大的治疗应用.
主要方法:
- 关于RNA疗法的科学文献审查,重点关注化学修饰,输送系统和新型RNA模式.
- 分析临床成果和技术创新,推动该领域的发展.
- 讨论新兴平台,如循环RNAs (circRNAs),自我放大mRNAs (saRNAs) 和ADAR指导的基数编辑器.
主要成果:
- RNA疗法2.0提供了增强的稳定性,可调性和针对性向特定器官和组织提供.
- 新的方法允许持久的蛋白质表达,可逆的转录重编码和精确的拼接调制.
- 肝外输送和人工智能增强设计方面的创新正在加速优化和扩大治疗潜力.
- 将RNA疗法与基因疗法结合起来,便于个性化医疗方法.
结论:
- RNA疗法已经转变为具有广泛治疗潜力的多功能和强大的药物类别.
- 化学,输送和新型RNA平台的持续进步正在为下一代基于RNA的精密医学铺平道路.
- 新兴技术有望解决瘤学,神经学,代谢障碍和罕见遗传疾病中的复杂疾病.
相关概念视频
RNA Splicing
61.0K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
61.0K
Microorganisms in Medicine and Therapeutics
1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Alternative RNA Splicing
25.5K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
25.5K
Alternative RNA Splicing
5.3K
5.3K
Riboswitches
9.9K
Riboswitches are non-coding mRNA domains that regulate the transcription and translation of downstream genes without the help of proteins. Riboswitches bind directly to a metabolite and can form unique stem-loop or hairpin structures in response to the amount of the metabolite present. They have two distinct regions – a metabolite-binding aptamer and an expression platform.
The aptamer has high specificity for a particular metabolite which allows riboswitches to specifically regulate...
The aptamer has high specificity for a particular metabolite which allows riboswitches to specifically regulate...
9.9K
What is Gene Expression?
11.9K
A gene is a stretch of DNA that serves as the blueprint for functional RNAs and proteins. Since DNA is comprised of nucleotides and proteins are comprised of amino acids, a mediator is required to convert the information encoded in DNA into proteins. This mediator is the messenger RNA (mRNA). mRNA copies the blueprint from DNA by a process called transcription. In eukaryotes, transcription occurs in the nucleus by complementary base-pairing with the DNA template. The mRNA is then...
11.9K


